Edition:
India

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

1.74USD
23 Feb 2018
Change (% chg)

$0.06 (+3.88%)
Prev Close
$1.67
Open
$1.66
Day's High
$1.80
Day's Low
$1.63
Volume
189,845
Avg. Vol
115,701
52-wk High
$3.78
52-wk Low
$1.09

Select another date:

Fri, Feb 23 2018

BRIEF-Corriente Advisors Reports 7.3 Pct Passive Stake In Catabasis Pharmaceuticals‍​

* CORRIENTE ADVISORS LLC REPORTS 7.3 PERCENT PASSIVE STAKE IN CATABASIS PHARMACEUTICALS INC AS OF FEBRUARY 16, 2018 - SEC FILING‍​ Source text : (http://bit.ly/2CDqdMi) Further company coverage:

BRIEF-Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression

* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT

BRIEF-Catabasis Pharmaceuticals reports third quarter financial results

* Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress

BRIEF-Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease

* Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 movedmd® trial evaluating Edasalonexent in duchenne muscular dystrophy and plans to initiate phase 3 clinical trial in first half 2018

Select another date: